The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition

被引:122
|
作者
Scherma, Maria [1 ,2 ]
Medalie, Julie [1 ]
Fratta, Walter [2 ]
Vadivel, Subramanian K. [3 ]
Makriyannis, Alexandros [3 ]
Piomelli, Daniele [4 ]
Mikics, Eva [5 ]
Haller, Jozsef [5 ]
Yasar, Sevil [6 ]
Tanda, Gianluigi [7 ]
Goldberg, Steven R. [1 ]
机构
[1] NIDA, Preclin Pharmacol Sect, Behav Neurosci Res Branch, Intramural Res Program,NIH,DHHS, Baltimore, MD USA
[2] Univ Cagliari, Bb Brodie Dept Neurosci, I-09124 Cagliari, Italy
[3] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA
[4] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA
[5] Hungarian Acad Sci, Inst Expt Med, Budapest, Hungary
[6] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA
[7] Natl Inst Drug Abuse, Psychobiol Sect, Med Discovery Res Branch, Intramural Res Program,NIH,Dept Hlth & Human Serv, Baltimore, MD 21224 USA
关键词
endogenous cannabinoids; anandamide; FAAH; URB597; WIN 55,212-2; conditioned place preferences; anxiety; locomotor activity; rats;
D O I
10.1016/j.neuropharm.2007.08.011
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Converging evidence suggests that the endocannabinoid. system is an important constituent of neuronal substrates involved in brain reward processes and emotional responses to stress. Here, we evaluated motivational effects of intravenously administered anandamide, an endogenous ligand for cannabinoid CB1-receptors, in Sprague-Dawley rats, using a place-conditioning procedure in which drugs abused by humans generally produce conditioned place preferences (reward). Anandamide (0.03-3 mg/kg intravenous) produced neither conditioned place preferences nor aversions. However, when rats were pre-treated with the fatty acid amide hydrolase (FAAH) inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester; 0.3 mg/kg intraperitoneal), which blocks anandamide's metabolic degradation, anandamide produced dose-related conditioned place aversions. In contrast, URB597 alone showed no motivational effects. Like URB597 plus anandamide, the synthetic CB1-receptor ligand WIN 55,212-2 (50-300 mu g/kg, intravenous) produced dose-related conditioned place aversions. When anxiety-related effects of anandamide and URB597 were evaluated in a light/dark box, both a low anandamide dose (0.3 mg/kg) and URB597 (0.1 and 0.3 mg/kg) produced anxiolytic effects when given alone, but produced anxiogenic effects when combined. A higher dose of anandamide (3 mg/kg) produced anxiogenic effects and depressed locomotor activity when given alone and these effects were potentiated after URB597 treatment. Finally, anxiogenic effects of anandamide plus URB597 and development of place aversions with URB597 plus anandamide were prevented by the CBI-receptor antagonist AM251 (3 mg/kg intraperitoneal). Thus, additive interactions between the effects of anandamide on brain reward processes and on anxiety may account for its aversive effects when intravenously administered during FAAH inhibition with URB597. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:129 / 140
页数:12
相关论文
共 50 条
  • [1] Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide
    Day, TA
    Rakhshan, F
    Deutsch, DG
    Barker, EL
    MOLECULAR PHARMACOLOGY, 2001, 59 (06) : 1369 - 1375
  • [2] The endogenous cannabinoid anandamide produces δ-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport
    Solinas, Marcello
    Tanda, Gianluigi
    Justinova, Zuzana
    Wertheim, Carrie E.
    Yasar, Sevil
    Piomelli, Daniele
    Vadivel, Subramanian K.
    Makriyannis, Alexandros
    Goldberg, Steven R.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (01): : 370 - 380
  • [3] Inhibition of Fatty Acid Amide Hydrolase (FAAH) by Macamides
    M. Alasmari
    M. Bӧhlke
    C. Kelley
    T. Maher
    A. Pino-Figueroa
    Molecular Neurobiology, 2019, 56 : 1770 - 1781
  • [4] Inhibition of Fatty Acid Amide Hydrolase (FAAH) by Macamides
    Alasmari, M.
    Bohlke, M.
    Kelley, C.
    Maher, T.
    Pino-Figueroa, A.
    MOLECULAR NEUROBIOLOGY, 2019, 56 (03) : 1770 - 1781
  • [5] Inhibition of Fatty Acid Amide Hydrolase (FAAH) by Macamides
    Alasmari, Moudi M.
    Bohlke, M.
    Kelley, C.
    Maher, T.
    Pino-Figueroa, A.
    FASEB JOURNAL, 2018, 32 (01):
  • [6] Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
    Cravatt, BF
    Demarest, K
    Patricelli, MP
    Bracey, MH
    Giang, DK
    Martin, BR
    Lichtman, AH
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) : 9371 - 9376
  • [7] Inhibition of fatty acid amide hydrolase (FAAH) augments the pharmacological effects of anandamide but lacks efficacy in mouse models of emotionality
    Pattipati, S. N.
    Varvel, S. A.
    Cravatt, B. F.
    Martin, B. R.
    Lichtman, A. H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S113 - S113
  • [8] The fatty acid amide hydrolase (FAAH)
    Ueda, N
    Puffenbarger, RA
    Yamamoto, S
    Deutsch, DG
    CHEMISTRY AND PHYSICS OF LIPIDS, 2000, 108 (1-2) : 107 - 121
  • [9] The fatty acid amide hydrolase (FAAH)
    Deutsch, DG
    Ueda, N
    Yamamoto, S
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2002, 66 (2-3): : 201 - 210
  • [10] Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats
    Fuellhase, Claudius
    Schreiber, Andrea
    Giese, Armin
    Schmidt, Michael
    Montorsi, Francesco
    Gratzke, Christian
    La Croce, Giovanni
    Castiglione, Fabio
    Stief, Christian
    Hedlund, Petter
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 (04) : 464 - 470